Loading…
Pacific Biosciences of California, Inc. is projected to decline to $1.23 by 2027, a -5% move from its current price of $1.29. PACB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.24 | $1.29 | $1.34 | -0.10% |
| May 30 | $1.21 | $1.29 | $1.36 | -0.21% |
| May 31 | $1.20 | $1.29 | $1.38 | -0.31% |
| Jun 1 | $1.18 | $1.28 | $1.40 | -0.42% |
| Jun 2 | $1.17 | $1.28 | $1.41 | -0.52% |
| Jun 3 | $1.16 | $1.28 | $1.42 | -0.63% |
| Jun 4 | $1.15 | $1.28 | $1.43 | -0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.15 | $1.28 | $1.43 | -0.73% |
| Week 2 | $1.09 | $1.27 | $1.48 | -1.45% |
| Week 3 | $1.04 | $1.26 | $1.53 | -2.17% |
| Week 4 | $1.01 | $1.25 | $1.56 | -2.88% |
| Week 5 | $0.974 | $1.24 | $1.59 | -3.59% |
| Week 6 | $0.9446 | $1.23 | $1.61 | -4.30% |
| Week 7 | $0.9178 | $1.23 | $1.64 | -4.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies.
The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data.
The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California, Inc. (PACB) is a healthcare company with a current price of $1.22 and a market capitalization of $378.93M, ranking 3281. The stock is categorized in Healthcare and operates within the sequencing solutions space.
The near-term technical picture shows bearish sentiment, but multi-year forecasts indicate upside potential across the horizon through 2050, with average prices rising from 2026 onward.
A major floor 40.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.2% below — buyers have tended to step in here.
The nearest ceiling, 34.9% above — a clean break opens room to run.
A major ceiling 107.0% above — clearing it would confirm fresh momentum.
Key PACB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PACB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.24 | Buy | $1.25 | Buy |
| MA 10 | $1.21 | Buy | $1.26 | Buy |
| MA 20 | $1.37 | Sell | $1.33 | Sell |
| MA 50 | $1.42 | Sell | $1.44 | Sell |
| MA 100 | $1.66 | Sell | $1.55 | Sell |
| MA 200 | $1.67 | Sell | $1.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.81 | Neutral |
| Stoch RSI (14) | 56.58 | Neutral |
| CCI (20) | -30.77 | Neutral |
| Williams %R (14) | -67.92 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -8.51 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 32.08 | Neutral |
| TRIX (15) | -0.72 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 62.28 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.28 | Buy |
| ADX (14) | 20.08 | Sell |
| ATR (14) | 0.05 | Info |
The near-term technical picture is bearish with RSI at 40. The stock trades below the 50-day simple moving average of $1.43 and the 200-day simple moving average of $1.67. Support is positioned at $1.12 and resistance at $1.74. The 30-day range spans from a low of $0.9187 to a high of $1.62, indicating a narrow, choppy price path near current levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $1.29 | $1.54 | 0% | Neutral | |
| $0.9239 | $1.23 | $1.75 | -5% | Neutral | |
| $0.9993 | $1.39 | $2.08 | +7% | Neutral | |
| $1.12 | $1.61 | $2.51 | +25% | Bullish | |
| $1.18 | $1.76 | $2.83 | +36% | Bullish | |
| $1.11 | $1.70 | $2.82 | +32% | Bullish | |
| $1.06 | $1.68 | $2.86 | +30% | Bullish | |
| $0.9747 | $1.58 | $2.75 | +23% | Bullish | |
| $0.9787 | $1.63 | $2.90 | +26% | Bullish | |
| $1.28 | $2.19 | $3.97 | +70% | Bullish | |
| $1.19 | $2.31 | $4.53 | +79% | Bullish | |
| $2.31 | $5.14 | $11.34 | +299% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.12 | $1.29 | $1.52 | +0.00% |
| June 2026 | $1.01 | $1.20 | $1.47 | -6.77% |
| July 2026 | $0.9748 | $1.17 | $1.46 | -2.49% |
| August 2026 | $0.9746 | $1.18 | $1.50 | +1.00% |
| September 2026 | $0.9208 | $1.13 | $1.45 | -4.72% |
| October 2026 | $0.8706 | $1.08 | $1.40 | -4.72% |
| November 2026 | $0.9022 | $1.12 | $1.47 | +4.34% |
| December 2026 | $0.9297 | $1.16 | $1.54 | +3.73% |
Click any year to see its month-by-month PACB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PACB to range from $1.12 to $1.54 through 2026. The $1.29 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PACB price prediction for 2027 points to an average of $1.23 (low $0.9239, high $1.75) — a potential decline of -5% on today's $1.29. Price action looks broadly range-bound.
In 2028, PACB is projected to trade between $0.9993 and $2.08, averaging $1.39 — a potential gain of +7% from today's $1.29. That is up +13% on the projected 2027 average. A consolidation phase looks the most probable path here.
Pacific Biosciences of California, Inc.'s 2029 outlook centres on $1.61, within a $1.12 to $2.51 range. That is up +16% on the projected 2028 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2030, PACB could reach as high as $2.83, with a base case around $1.76 and support toward $1.18 — roughly +36% from $1.29. Buyers look set to stay in control over this stretch.
Expect PACB to range from $1.11 to $2.82 through 2031. The $1.70 average target implies a +32% move from current prices. That is -3% versus the projected 2030 average. Momentum favours further upside here.
The PACB price prediction for 2032 points to an average of $1.68 (low $1.06, high $2.86) — a potential gain of +30% on today's $1.29. Buyers look set to stay in control over this stretch.
In 2033, PACB is projected to trade between $0.9747 and $2.75, averaging $1.58 — a potential gain of +23% from today's $1.29. That is -6% versus the projected 2032 average. Momentum favours further upside here.
Pacific Biosciences of California, Inc.'s 2034 outlook centres on $1.63, within a $0.9787 to $2.90 range. That is up +3% on the projected 2033 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PACB could reach as high as $3.97, with a base case around $2.19 and support toward $1.28 — roughly +70% from $1.29. Momentum favours further upside here.
Expect PACB to range from $1.19 to $4.53 through 2040. The $2.31 average target implies a +79% move from current prices. That is up +5% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PACB price prediction for 2050 points to an average of $5.14 (low $2.31, high $11.34) — a potential gain of +299% on today's $1.29. Momentum favours further upside here.
Investing $1,000 in PACB today (≈ 775.193798 PACB) could be worth
$3,986.89
+$2,986.89 (+299%) by 2050 · US Dollar
Based on the average projected PACB price of $5.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PACBwould be worth at today's price.
$1,000 invested in PACB on May 27, 2025 (≈ 1,098.901067 PACB) would be worth
$1,417.58
+$417.58 (+41.8%) today · 1.42× · US Dollar
Based on a PACB entry price of $0.91 vs. today's $1.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.19 | $1,084.03 | +8.4% |
| 1 month ago | $1.59 | $811.32 | -18.9% |
| 3 months ago | $1.78 | $724.72 | -27.5% |
| 6 months ago | $2.32 | $556.03 | -44.4% |
| 1 year ago | $0.91 | $1,417.58 | +41.8% |
| All time (5.0y) ago | $26.42 | $48.83 | -95.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PACB forecast.
Our base-case forecast reaches $2.60 around 2050.
Implied market cap at $2.60: $807.56M
The multi-year forecast shows a bullish drift from 2026 through 2050. In 2026 the average price is $1.22 with a 0% ROI. The 2027 forecast yields an average of $1.15 and a -5.7% ROI, followed by 2028 at $1.33 with a 9.1% ROI.
The trend strengthens into 2029 with an average of $1.53 and a 25.5% ROI, and into 2030 with an average of $1.68 and a 37.6% ROI. By 2035 the average price reaches $2.09 with a 71.7% ROI, and by 2040 it reaches $2.20 with an 80.5% ROI. The final long-run projection places the 2050 average at $4.94 with a 305% ROI.
Investors should treat these forecasts as estimates, not guarantees, and recognize that outcomes may differ due to market dynamics.
Tap a question to reveal the answer.
Avg price is $1.68 with a 37.6% ROI and bullish sentiment.
Yes. Forecasts show bullish sentiment from 2029 onward, including 2029 avg $1.53 (ROI 25.5%), 2030 avg $1.68 (ROI 37.6%), 2035 avg $2.09 (ROI 71.7%), 2040 avg $2.20 (ROI 80.5%), and 2050 avg $4.94 (ROI 305%).
Min forecast in 2027 is $0.8613, with an average of $1.15 and a max of $1.66 (ROI -5.7%).
Yes, the 2050 forecast shows a max of $11.11, with an average of $4.94 and a 305% ROI.
Current price is $1.22 and market cap is $378.93M, with a rank of 3281.
Pacific Biosciences of California, Inc. Community Discussion
0Share your Pacific Biosciences of California, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.